Capsaicin is a chemical compound that gives chili peppers their spicy flavor and heat.
Biological activity, capsaicin has been reported to exhibit a range of effects, including:
Pain relief: 10-50 μM
Anti-inflammatory activity: 20-50 μM
Antioxidant activity: 10-100 μM
Anti-cancer activity: 50-100 μM
Cardiovascular health: 20-50 μM
Approximate μM concentrations of capsaicin, the active compound in chili peppers, that can be achieved with different amounts of chili peppers:
1 teaspoon of dried chili pepper flakes (5g):~10-50 μM of capsaicin
1 tablespoon of dried chili pepper flakes (15g): ~30-150 μM of capsaicin
1 cup of fresh chili peppers (100g): ~100-500 μM of capsaicin
1 teaspoon of chili pepper extract (5g): ~100-500 μM of capsaicin
1 tablespoon of chili pepper extract (15g): ~300-1500 μM of capsaicin
Approximate μM concentrations of capsaicin in various foods that contain capsaicin:
Jalapeño peppers: 1 pepper (20g): ~20-100 μM of capsaicin 2–8 mg/100g of fresh Jalapeño
Serrano peppers: 1 pepper (10g): ~10-50 μM of capsaicin 5–15 mg/100g
Cayenne peppers: 1 pepper (10g): ~50-200 μM of capsaicin
Habanero peppers: 1 pepper (20g): ~100-500 μM of capsaicin 15–30 mg/100g
Ghost peppers: 1 pepper (20g): ~200-1000 μM of capsaicin
Hot sauce: 1 teaspoon (5g): ~10-50 μM of capsaicin
Chili flakes: 1 teaspoon (5g): ~10-50 μM of capsaicin
Spicy sauces and marinades: 1 tablespoon (15g): ~10-50 μM of capsaicin
Cayenne Pepper Powder – Approximate capsaicin content: roughly 5–20 mg/g (15-30g human for 100uM?)
-IC50 in Cancer Cell Lines: Approximately 50–300 µM (consume 150mg of capsaican not possible?)
-IC50 in Normal Cell Lines: Generally higher—often 2–3 times greater
Pathways:
-disrupting mitochondrial membrane potential, leading to cytochrome c release and subsequent activation of caspases
-Activation of TRPV1: resulting in increased intracellular calcium levels
-capsaicin can lead to increased production of ROS within cancer cells
-Inhibition of NF-κB
-Inhibit PI3K/AKT/mTOR signaling
-STAT3 Inhibition
-Cell Cycle Arrest
-reduce the expression of vascular endothelial growth factor (VEGF)
-COX-2
-capsaicin is a natural ADAM10 activator and shows potential to attenuate amyloid pathology and protect against AD
Capsaicin — capsaicin is a pungent vanilloid alkaloid phytochemical from Capsicum peppers and the principal TRPV1 agonist responsible for chili heat. It is best classified as a natural product / small-molecule vanilloid with approved topical analgesic use but no established anticancer indication. Standard abbreviations include CAP and CAPS. In cancer literature it is a pleiotropic stressor whose dominant preclinical effects usually converge on Ca2+ influx, mitochondrial dysfunction, ROS generation, suppression of pro-survival signaling, and apoptosis, but its biology is context- and concentration-dependent, with occasional low-dose pro-migratory / pro-metastatic signaling reported.
Primary mechanisms (ranked):
- TRPV-linked cation influx with intracellular Ca2+ dysregulation, variably via TRPV1 or other TRPV-family context such as TRPV6
- Mitochondrial injury with loss of membrane potential, cytochrome c release, and intrinsic apoptotic execution
- Mitochondrial and cellular ROS increase with redox stress exceeding tumor buffering capacity
- Suppression of STAT3 and related survival transcription programs in multiple models
- Suppression of NF-κB-centered inflammatory / survival signaling, with downstream anti-migratory and radiosensitizing implications in some settings
- PI3K/Akt/mTOR attenuation and cell-cycle restraint in responsive models
- Contextual induction of autophagy as a stress-adaptation program that may either accompany death or partially buffer it
- Anti-migratory / anti-invasive effects in many models, but with an important low-concentration exception in some colorectal systems
Bioavailability / PK relevance: Capsaicin is lipophilic, rapidly absorbed, and rapidly metabolized, with substantial first-pass limitation after oral exposure. Human oral PK from a capsicum preparation containing 26.6 mg capsaicin produced a Cmax of about 2.47 ng/mL at ~47 minutes, while the FDA-approved 8% topical system produced transient systemic exposure usually below 5 ng/mL, with a highest detected plasma level of 4.6 ng/mL. Delivery is therefore a major translation constraint for anticancer use, and formulation-based approaches are often invoked to overcome short half-life, irritancy, and exposure limits.
In-vitro vs systemic exposure relevance: This is a major limitation. Many anticancer cell studies use roughly 10–300 µM, whereas reported human plasma exposures from oral or approved topical use are in the low ng/mL range, approximately ~0.008–0.015 µM, i.e., orders of magnitude lower than many cytotoxic in-vitro concentrations. Accordingly, direct systemic tumoricidal translation from standard dietary or approved topical exposure is weak unless local delivery, sustained-release systems, or substantially altered formulations are used.
Clinical evidence status: Anticancer evidence is predominantly preclinical, with in-vitro and some in-vivo support across several tumor types. There is no regulatory approval for cancer treatment. Human oncology use is currently much more credible as supportive care for neuropathic pain, especially chemotherapy-induced peripheral neuropathy, where topical high-concentration capsaicin patches are being studied and used off-label / investigationally, rather than as a direct antitumor therapy.
Mechanistic Table
| Rank |
Pathway / Axis |
Cancer Cells |
Normal Cells |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
TRPV-linked Ca2+ influx |
Ca2+ ↑; death signaling ↑ |
Sensory excitation ↑; irritancy ↑ |
P/R |
Upstream trigger |
Usually framed through TRPV1, but some tumor models show dependence on other TRPV-family context such as TRPV6; this is mechanistically central but not uniform across cancers. |
| 2 |
Mitochondrial membrane potential |
MMP ↓; cytochrome c release ↑ |
↔ / stress if exposed |
R |
Intrinsic apoptosis initiation |
Mitochondrial dysfunction is one of the most reproducible downstream events and often links Ca2+ overload with apoptosis. |
| 3 |
Mitochondrial ROS increase |
ROS ↑; redox buffering overwhelmed |
↔ / antioxidant response may compensate |
P/R |
Stress amplification |
Frequently sits upstream of mitochondrial collapse, DNA damage signaling, and apoptosis; cancer selectivity is often attributed to weaker redox reserve. |
| 4 |
Intrinsic apoptosis machinery |
BAX/Bak ↑; Bcl-2/Bcl-xL ↓; caspase-3/9 ↑ |
↔ / lower sensitivity in some comparisons |
R/G |
Execution-phase cell death |
Common endpoint across responsive models; often follows ROS and mitochondrial injury rather than acting as the primary initiating lesion. |
| 5 |
STAT3 survival signaling |
STAT3 ↓ |
↔ |
R/G |
Reduced survival and proliferation |
Well supported in multiple myeloma and other models, but not universal; note that a HepG2 context reported ROS-associated STAT3 activation coupled to autophagy. |
| 6 |
NF-κB inflammatory survival axis |
NF-κB ↓ |
Inflammatory tone ↓ |
R/G |
Anti-survival; anti-migratory |
Important for invasion restraint and likely part of observed radiosensitization in some models. |
| 7 |
PI3K Akt mTOR axis |
PI3K/Akt/mTOR ↓ |
↔ |
R/G |
Growth suppression |
Seen in several responsive systems, but this axis is also part of the cautionary low-dose pro-metastatic literature in colorectal cancer. |
| 8 |
Cell-cycle control |
G0/G1 or G1/S arrest ↑ |
↔ |
G |
Proliferation blockade |
Usually secondary to upstream stress and survival-pathway suppression rather than the earliest event. |
| 9 |
Autophagy stress program |
Autophagy ↑ (context-dependent) |
↔ |
G |
Adaptive buffering or co-lethal stress |
In HepG2, autophagy appeared partially protective because inhibiting it enhanced capsaicin-induced apoptosis. |
| 10 |
Migration invasion EMT phenotype |
Migration ↓; invasion ↓; EMT ↓ (context-dependent) |
↔ |
G |
Anti-metastatic phenotype |
Frequently reported at active doses, often linked to AMPK activation and NF-κB suppression. |
| 11 |
Low-dose paradox flag |
ROS ↑ with Akt/mTOR ↑ and STAT3 ↑ (model-dependent) |
↔ |
G |
Potential pro-metastatic signaling |
Important caution: low-concentration capsaicin has been reported to enhance metastatic behavior in colorectal cancer models. |
| 12 |
Radiosensitization or Chemosensitization |
Sensitivity ↑ (context-dependent) |
Unknown |
G |
Adjunct potential |
Preclinical support exists, especially via NF-κB and stress-pathway modulation, but this remains non-clinically established for direct cancer treatment. |
| 13 |
Clinical Translation Constraint |
Required tumoricidal exposure often not reached systemically |
Irritation and tolerability limit escalation |
G |
Translation bottleneck |
Typical antitumor in-vitro concentrations greatly exceed known plasma exposure from standard oral intake or approved topical use; formulation, local delivery, and tumor heterogeneity are major constraints. |
P: 0–30 min
R: 30 min–3 hr
G: >3 hr
|